| Federal Response Blog Posts | |
| AHEAD Dashboard - EHE Indicators: PrEP Coverage | |
| America’s HIV Epidemic Analysis Dashboard (AHEAD) is a unique data visualization tool to empower local stakeholders to track progress towards the goals of the Ending the HIV Epidemic: A Plan for America (EHE) initiative. Today, we start a new blog series providing detailed information on each of the six EHE indicators tracked in AHEAD, beginning with pre-exposure prophylaxis (PrEP) coverage. | |
| |
| COVID-19 Resources for the HIV Community | |
| As we move into September and the start of a new season, we continue to update COVID-19 and People with HIV, our HIV.gov page of resources from agencies across the federal government. These fact sheets, guidelines, and other resources are available to assist those who continue to provide access to HIV prevention, treatment, and care services in the context of the COVID-19 pandemic. | |
|
| Supporting Engagement & Re-engagement in HIV Care to End the HIV Epidemic in Baltimore | |
| “Unapologetically enabling” is the mantra of the Baltimore City Health Department’s Getting to Zero + Initiative, which employs novel approaches to support clients with engagement and re-engagement in HIV care. Dr. Victoria A. Cargill, Assistant Commissioner of the Baltimore City Health Department, discussed the program at the 2020 Ryan White HIV/AIDS Program Clinical Conference. | |
|
| Large NIH Clinical Trial Illuminates Long-Term Health Effects of HIV | |
| Initial data from a large NIH-supported clinical trial offer a detailed look at the health status of people aging with HIV around the world. With 7,770 participants enrolled in 12 countries across five continents, the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) is evaluating the ability of a statin medication, pitavastatin, to reduce the risk of heart disease among people with HIV. | |
|
| Long-Acting Injectables Hold Promise for Maintaining Viral Suppression and Preventing HIV—Highlights from the Ryan White Clinical Conference | |
| The promise of long-acting injectable formulations of HIV medications to maintain viral load suppression is closer to reality, according to Constance A. Benson, MD, Professor of Medicine and Global Public Health at University of California San Diego. She shared her assessment during a session at the 2020 Ryan White HIV/AIDS Program Clinical Conference, held online earlier this month. | |
|
No hay comentarios:
Publicar un comentario